Insulin lispro

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

Retrieved on: 
Thursday, June 2, 2022
Health, FDA, Medical Devices, Diabetes, Clinical Trials, Research, Science, Insulin analog, Company, Research, Knowledge, Prediabetes, Pharmacokinetics, Pharmacology, Physician, FDA, Insulin, Biosimilar, Diabetes, Obesity, Clinical trial, Insulin lispro, Drug development, Civica Rx, AP, Safety, Insulin aspart, Pancreas, Pharmaceutical industry, Insulin glargine, Civica, Profil

Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.

Key Points: 
  • Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
  • Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.
  • With its extensive experience and quality track record, Profil is the ideal clinical trial partner for Civica.
  • More information on Civica and its affordable insulin initiative, including commentary from partners and a fact sheet, can be found at https://civicainsulin.org .

Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults

Retrieved on: 
Wednesday, April 27, 2022
Diabetes, Health, Medical Devices, People, Glycated hemoglobin, CLIO, Quality of life, CGM, NASDAQ, Sleep, Hearing, Safety, Insulin aspart, Pregnancy, CT, ATTD, Meal, Manning M. Knapp, Treatment, Implementation, Technology, Population, Poster, Start, Hydroxycarbamide, Honda advanced technology, Pediatrics, Twitter, Doctor of Education, MDI, Type 1, Conference, MS, Adoption, Insulin, Pros, Veni, vidi, vici, Dialysis, Tandem, Medicine, International Conference on Information Systems Security and Privacy, MRI, Department, MD, Tandem Diabetes Care, Insulin lispro, Behavioural sciences, Hospital, Initiation, Pharmaceutical industry, Medical device, Dentistry, Diabetes, System

Separate from the CLIO study, researchers retrospectively studied the first 90 days of pump activation in MDI users transitioning to the t:slim X2 pump with Control-IQ technology.

Key Points: 
  • Separate from the CLIO study, researchers retrospectively studied the first 90 days of pump activation in MDI users transitioning to the t:slim X2 pump with Control-IQ technology.
  • The results showed that 95 percent of MDI users successfully initiated Control-IQ technology within 14 days of pump start.
  • Long-Term Improvements In Patient-Reported Outcomes Irrespective of Baseline Glycemic Control and Previous Insulin Delivery Method with the t:Slim X2 Pump with Control-IQ Technology.
  • Important Safety Information: The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately).

Slone Partners Places Richard B. Bartram as Chief Financial Officer at MBX Biosciences

Retrieved on: 
Tuesday, April 26, 2022
People, Biotechnology, Degenerative disease, Esperies, PEPS, New Enterprise Associates, PEP, CFO, Patient, Michigan State University, LinkedIn, Growth, Precision medicine, Associate, MBX, Teriparatide, Bartram, Certified Public Accountant, Hypoparathyroidism, PricewaterhouseCoopers, Esperion Therapeutics, Therapy, Pharmaceutical industry, Management, Insulin lispro

SOUTH RIDING, Va., April 26, 2022 /PRNewswire-PRWeb/ -- Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Richard B. Bartram as Chief Financial Officer (CFO) at MBX Biosciences, a clinical stage biopharmaceutical company developing peptide therapeutics with a focus on the treatment of endocrine disorders.

Key Points: 
  • "Rick Bartram is a tremendously talented and respected business leader with an outstanding track record of success over many years," said Slone Partners CEO Leslie Loveless .
  • "He is a savvy financial strategist, operational planner, and trusted business partner, and will be a wonderful addition to the MBX executive team."
  • "I am thrilled to join MBX Biosciences at such an exciting time of opportunity for the company," said Bartram.
  • Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations People Are Our Science.

The Global Insulin Syringes Market Will Grow to USD 2.1 Billion by 2027, at a CAGR of 4.5% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 20, 2022
Health, General Health, People, Type 2, Insulin, Center, Korea Disease Control and Prevention Agency, Syringe, American Diabetes Association, Obesity, Population, CDC, COVID-19, Adult, WHO, CSII, Ageing, Viatris, Medicine, Incidence, Diabetes, CAGR, US FDA, Hospital, World, Patient, Eli Lilly and Company, Growth, Mortality, Technology, Company, US, Clifton Springs Hospital & Clinic, Public health, USD, Partnership, City, End user, FDA, Eli Lilly, Industry, World Health Organization, Pharmaceutical industry, Borosilicate glass, Lilly, Insulin glargine, Disease, Cipla, Dulaglutide, Insulin lispro

The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period.
  • On the basis of Disease, the insulin syringe market is segmented into Type 1 Diabetes and Type 2 Diabetes.
  • Type 2 Diabetes is expected to account for the largest revenue share in the Insulin Syringes Market by 2020.
  • North America is expected to be the leading region in the Insulin Syringes Market by 2020, with the largest revenue share.

JDRF Announces Support of Civica to Manufacture and Distribute Low-Cost Insulin

Retrieved on: 
Thursday, March 3, 2022
Mayo Clinic, Automated insulin delivery systems, Cranial nerve disease, Critical care, Research, Human, HCA Healthcare, Blue Cross, Industry, Diet, Hospital, Leona, Death, Twitter, Insulin, Eye, Insulin lispro, Civica, Trinity, SSM Health, Insulin aspart, Program, JDRF, Volunteering, Trinity Health, Efficiency, CommonSpirit Health, Intermountain Healthcare, Multimedia, Food, Private sector, Pharmacy, Type 1 diabetes, Kidney, Immune system, Health, Arnold Ventures LLC, BCBS, Pancreas, Blue Cross Blue Shield Association, Pharmaceutical industry, T1D, Transcare EMS, Instagram, Kaiser Permanente, Insulin glargine, Facebook

The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.

Key Points: 
  • The project will manufacture and distribute three low-cost biosimilar insulin options to enable anyone to purchase insulin at no more than $30/vial and $55/box of five pens, regardless of insurance status.
  • "The Civica insulin development project is a tremendous step forward to make insulin accessible for all, regardless of insurance status, and address a national crisis," saidAaron Kowalski, Ph.D., JDRF CEO.
  • Hospital advisorsdoctors and pharmacistsprioritize the essential medicines Civica provides for use in acute and critical care, emergency rooms, and surgery.
  • Civica has since launched CivicaScript, focused on lowering prices at the pharmacy counter and The Civica Foundation, dedicated to fostering philanthropic support for manufacturing and distributing essential medicines.

Adocia announces 2021 fourth quarter financial results

Retrieved on: 
Wednesday, February 23, 2022
IAS, Peptide, Glucagon, Diabetes, Insulin lispro, Industry, Exenatide, Company, IFRS, Safety, Hypoglycemia, Lists of diseases, Protein, Insulin glargine, Obesity, Combo, Patient, Technology, Insulin, Research, Film, Pharmaceutical industry, EUR

The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.

Key Points: 
  • The revenue recorded for the year 2021 (EUR 1.4 million) reflects the progress of research and development services provided by Adocia in connection with the transfer and development of products as contracted in 2018.
  • The Company had a cash position of EUR 15.2 million as of December 31, 2021, compared to EUR 28.1 million as of December 31, 2020.
  • Cash consumption for the year 2021 amounts to EUR 19.9 million and stands below last year's level (EUR 22.5 million), on a comparable basis (excluding financing operations).
  • Net financial liabilities (excluding derivative debts impacts) amounted to EUR 33.3 million as of December 31, 2021, compared with EUR 27.3 million as of December 31, 2020.

Capillary Biomedical Receives FDA Approval to Begin Pivotal Trial of Its SteadiFlow Seven-Day-Wear Infusion Set Technology

Retrieved on: 
Wednesday, January 19, 2022
FDA, Diabetes, Medical Devices, Health, Clinical Trials, Ageing, Patient, Technology, Insulin, Inflammation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Extended-wear hearing aid, IDE, Pain, Cannula, Skin, Diabetes, Insulin aspart, CRO, Quality of life, Doctor of Philosophy, MD, Food, FDA, Maintenance, Medical device, Insulin lispro

Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.

Key Points: 
  • Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to start a pivotal trial for the assessment of its SteadiFlow seven-day-wear infusion set technology.
  • CapBios SteadiSet infusion set, powered by its SteadiFlow technology platform, is designed to increase the wear time of insulin infusion sets by addressing the common causes of infusion site failure.
  • With this pivotal trial we are pleased to be taking a significant next step in the evolution of our SteadiFlow infusion set, said CapBio CEO Paul Strasma.
  • The Companys first product, the SteadiSet infusion set featuring SteadiFlow technology, is designed to improve the comfort, reliability and predictability of insulin pump therapy.

Adocia announces its financial calendar for 2022

Retrieved on: 
Thursday, January 6, 2022
Safety, Patient, Obesity, Hypoglycemia, Mission statement, Protein, Combo, Lists of diseases, Glucagon, Diabetes, Insulin glargine, Euronext Paris, GLOBE, Exenatide, Technology, ADOC, Peptide, Industry, Insulin, Insulin lispro, Beauty salon, Pharmaceutical industry

LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.

Key Points: 
  • LYON, France, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ADOCIA SA, a French socit anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatments and other metabolic diseases with innovative formulations of peptides and proteins, announced today its financial calendar for 2022.
  • Publication of revenue for Q1 2022.
  • Publication of mid-year financial statements as of June 30, 2022.
  • In addition to regular meetings with the financial community, investors can also find updated information on the companys website ( www.adocia.com ).

Adocia to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Friday, September 10, 2021

The H.C. Wainwright webcast will be available on-demand to those attending the conference virtually starting Monday, September 13th, 2021 at 7:00 AM ET.

Key Points: 
  • The H.C. Wainwright webcast will be available on-demand to those attending the conference virtually starting Monday, September 13th, 2021 at 7:00 AM ET.
  • Investors attending the conference virtually who are interested in meeting with Company management should contact their H.C. Wainwright representative.
  • Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases.
  • The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone Glucagon) for the treatment of hypoglycemia.

US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026: First FDA Approved Interchangeable Biosimilar Insulin Cost & Dosage Insight - ResearchAndMarkets.com

Retrieved on: 
Monday, August 23, 2021
Medical Devices, Health, Insulin lispro, Publication, FDA, Insulin, Research, Government, Private sector, Growth, Patent, Insulin aspart, Pharmaceutical industry, Generic drug

The "US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • The biosimilar insulin is processed in a way that it almost mimics the action of the original insulin product.
  • Approval of Semglee as first interchangeable insulin biosimilar is believed to act as a revolutionary step for the US insulin biosimilar market, which simplifies the path of approval for other investigational biosimilars.
  • The report also involves the comparative price analysis along with the clinical trends, market drivers and possible challenges related to US insulin biosimilar market.